Cargando…

Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543

[Image: see text] The neuronal glycine transporter GlyT2 modulates inhibitory glycinergic neurotransmission by controlling the extracellular concentration of synaptic glycine and the supply of neurotransmitter to the presynaptic terminal. Spinal cord glycinergic neurons present in the dorsal horn di...

Descripción completa

Detalles Bibliográficos
Autores principales: Benito-Muñoz, Cristina, Perona, Almudena, Felipe, Raquel, Pérez-Siles, Gonzalo, Núñez, Enrique, Aragón, Carmen, López-Corcuera, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691691/
https://www.ncbi.nlm.nih.gov/pubmed/34003005
http://dx.doi.org/10.1021/acschemneuro.0c00602
_version_ 1784618810179846144
author Benito-Muñoz, Cristina
Perona, Almudena
Felipe, Raquel
Pérez-Siles, Gonzalo
Núñez, Enrique
Aragón, Carmen
López-Corcuera, Beatriz
author_facet Benito-Muñoz, Cristina
Perona, Almudena
Felipe, Raquel
Pérez-Siles, Gonzalo
Núñez, Enrique
Aragón, Carmen
López-Corcuera, Beatriz
author_sort Benito-Muñoz, Cristina
collection PubMed
description [Image: see text] The neuronal glycine transporter GlyT2 modulates inhibitory glycinergic neurotransmission by controlling the extracellular concentration of synaptic glycine and the supply of neurotransmitter to the presynaptic terminal. Spinal cord glycinergic neurons present in the dorsal horn diminish their activity in pathological pain conditions and behave as gate keepers of the touch-pain circuitry. The pharmacological blockade of GlyT2 reduces the progression of the painful signal to rostral areas of the central nervous system by increasing glycine extracellular levels, so it has analgesic action. O-[(2-benzyloxyphenyl-3-fluorophenyl)methyl]-l-serine (ALX1393) and N-[[1-(dimethylamino)cyclopentyl]methyl]-3,5-dimethoxy-4-(phenylmethoxy)benzamide (ORG25543) are two selective GlyT2 inhibitors with nanomolar affinity for the transporter and analgesic effects in pain animal models, although with deficiencies which preclude further clinical development. In this report, we performed a comparative ligand docking of ALX1393 and ORG25543 on a validated GlyT2 structural model including all ligand sites constructed by homology with the crystallized dopamine transporter from Drosophila melanogaster. Molecular dynamics simulations and energy analysis of the complex and functional analysis of a series of point mutants permitted to determine the structural determinants of ALX1393 and ORG25543 discrimination by GlyT2. The ligands establish simultaneous contacts with residues present in transmembrane domains 1, 3, 6, and 8 and block the transporter in outward-facing conformation and hence inhibit glycine transport. In addition, differential interactions of ALX1393 with the cation bound at Na1 site and ORG25543 with TM10 define the differential sites of the inhibitors and explain some of their individual features. Structural information about the interactions with GlyT2 may provide useful tools for new drug discovery.
format Online
Article
Text
id pubmed-8691691
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-86916912021-12-22 Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543 Benito-Muñoz, Cristina Perona, Almudena Felipe, Raquel Pérez-Siles, Gonzalo Núñez, Enrique Aragón, Carmen López-Corcuera, Beatriz ACS Chem Neurosci [Image: see text] The neuronal glycine transporter GlyT2 modulates inhibitory glycinergic neurotransmission by controlling the extracellular concentration of synaptic glycine and the supply of neurotransmitter to the presynaptic terminal. Spinal cord glycinergic neurons present in the dorsal horn diminish their activity in pathological pain conditions and behave as gate keepers of the touch-pain circuitry. The pharmacological blockade of GlyT2 reduces the progression of the painful signal to rostral areas of the central nervous system by increasing glycine extracellular levels, so it has analgesic action. O-[(2-benzyloxyphenyl-3-fluorophenyl)methyl]-l-serine (ALX1393) and N-[[1-(dimethylamino)cyclopentyl]methyl]-3,5-dimethoxy-4-(phenylmethoxy)benzamide (ORG25543) are two selective GlyT2 inhibitors with nanomolar affinity for the transporter and analgesic effects in pain animal models, although with deficiencies which preclude further clinical development. In this report, we performed a comparative ligand docking of ALX1393 and ORG25543 on a validated GlyT2 structural model including all ligand sites constructed by homology with the crystallized dopamine transporter from Drosophila melanogaster. Molecular dynamics simulations and energy analysis of the complex and functional analysis of a series of point mutants permitted to determine the structural determinants of ALX1393 and ORG25543 discrimination by GlyT2. The ligands establish simultaneous contacts with residues present in transmembrane domains 1, 3, 6, and 8 and block the transporter in outward-facing conformation and hence inhibit glycine transport. In addition, differential interactions of ALX1393 with the cation bound at Na1 site and ORG25543 with TM10 define the differential sites of the inhibitors and explain some of their individual features. Structural information about the interactions with GlyT2 may provide useful tools for new drug discovery. American Chemical Society 2021-05-18 /pmc/articles/PMC8691691/ /pubmed/34003005 http://dx.doi.org/10.1021/acschemneuro.0c00602 Text en © 2021 American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Benito-Muñoz, Cristina
Perona, Almudena
Felipe, Raquel
Pérez-Siles, Gonzalo
Núñez, Enrique
Aragón, Carmen
López-Corcuera, Beatriz
Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543
title Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543
title_full Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543
title_fullStr Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543
title_full_unstemmed Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543
title_short Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543
title_sort structural determinants of the neuronal glycine transporter 2 for the selective inhibitors alx1393 and org25543
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691691/
https://www.ncbi.nlm.nih.gov/pubmed/34003005
http://dx.doi.org/10.1021/acschemneuro.0c00602
work_keys_str_mv AT benitomunozcristina structuraldeterminantsoftheneuronalglycinetransporter2fortheselectiveinhibitorsalx1393andorg25543
AT peronaalmudena structuraldeterminantsoftheneuronalglycinetransporter2fortheselectiveinhibitorsalx1393andorg25543
AT feliperaquel structuraldeterminantsoftheneuronalglycinetransporter2fortheselectiveinhibitorsalx1393andorg25543
AT perezsilesgonzalo structuraldeterminantsoftheneuronalglycinetransporter2fortheselectiveinhibitorsalx1393andorg25543
AT nunezenrique structuraldeterminantsoftheneuronalglycinetransporter2fortheselectiveinhibitorsalx1393andorg25543
AT aragoncarmen structuraldeterminantsoftheneuronalglycinetransporter2fortheselectiveinhibitorsalx1393andorg25543
AT lopezcorcuerabeatriz structuraldeterminantsoftheneuronalglycinetransporter2fortheselectiveinhibitorsalx1393andorg25543